Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Investigation of gene expression in human brain samples

ABSTRACT: Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by a gradual decline in neuronal activity, which affects memory and thinking. As it progresses, it can interfere with daily life, and it can eventually lead to death. AD accounts for approximately 60-70% of dementia cases and is particularly prevalent in the elderly. However, the gene regulatory mechanism for AD development in human brain tissues is still unclear. To deepen our understanding of the molecular mechanims involved in this cognitive decline, we conducted RNA-sequencing (RNA-seq) on six brain tissues from both control (Ct) without dementia and AD patients to analyze differentially expressed genes (DEGs) between Ct and AD brains.

ORGANISM(S): Homo sapiens

PROVIDER: GSE328648 | GEO | 2026/09/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Proteomic changes linked to the limbic stage of AD

Project description:Alzheimer's disease (AD) is a neurodegenerative disorder and the most common cause of dementia worldwide. In AD, neurodegeneration spreads throughout the brain cortex in a gradual and predictable pattern, causing progressive memory decline and cognitive impairment. Here, we conducted proteomic, acetylomic and phosphoproteomic analyses of human postmortem tissue samples from AD (Braak stage III-IV) and control brains, covering all anatomical areas affected during the limbic stage of the disease (total hippocampus, CA1, entorhinal and perirhinal cortices). A total of 58 tissues were analyzed by nanoLC-MS/MS.

2021-12-30 | PXD027173 | Pride

ChIP-seq studies to ATF4, OLIG2, THRA binding sites of AD brain samples

Project description:We performed the Chip-seq to brain tissues from prefrontal cortex region in AD Postmortem samples and non-dementia control postmortem samples.

2019-10-31 | GSE129039 | GEO

Fibronectin mediates the interaction between vascular pathology and Alzheimer’s disease by inhibiting homeostatic gliovascular crosstalk

Project description:Alzheimer's disease (AD) often coexists with cerebrovascular pathology (CVP), contributing to cognitive decline and dementia. Understanding the molecular interplay between these pathologies is vital for developing effective therapies that can address the complexities of AD. The extracellular matrix (ECM) plays a crucial role in maintaining the blood-brain barrier (BBB) and modulating interactions of brain cell types with the vasculature. Elevated levels of a particular ECM component, Fibronectin 1 (FN1) are associated with both AD and vascular dysfunctions. In this study we show the molecular regulation exerted by FN1 to regulate the homeostatic interaction between vasculature and the brain.

2026-07-02 | GSE268780 | GEO

AETA peptide contributes to Alzheimer’s disease signature of synapse dysfunction

Project description:Alzheimer’s disease (AD), the leading cause of dementia, is characterized by early synaptic dysfunction that precedes overt cognitive decline. While amyloid-β and Tau remain central to AD pathogenesis, molecular triggers of synapse weakening remain unclear. Here, we investigated AETA, a novel brain-secreted peptide derived from amyloid precursor protein (APP), as a potential mediator of synapse dysfunction in AD. We previously identified AETA as a unique modulator of NMDA receptor activity in the healthy brain; however, its role in AD etiology was yet to be explored. Post-mortem analyses of human hippocampal and prefrontal cortex tissues revealed significantly elevated AETA levels in AD patients, particularly in females. To further explore the contribution of AETA to AD synaptic pathology, we analyzed a new mouse model, the AETA-m mouse, exhibiting chronically increased brain AETA expression. Hippocampi of female AETA-m mice display an increase in the number of astrocyte and microglia, but no overt neuroinflammation. RNA sequencing of female AETA-m hippocampi revealed alterations in synaptic gene expression that closely paralleled those observed in vulnerable human AD brain regions, most notably in the hippocampus. These two phenotypes were absent in males. Functionally, hippocampal neurons from AETA-m mice displayed impaired NMDA receptor signaling, dendritic spine loss, and memory deficits especially in females, mirroring early AD-associated synaptic dysfunction. Together, these findings identify AETA as a novel key contributor of synaptic vulnerability in AD and associated memory processing, especially in females. Targeting AETA signaling may, therefore, offer new therapeutic avenues for preventing or mitigating synaptic and cognitive decline in AD.

2026-06-10 | GSE333329 | GEO

Genome-wide DNA methylation analysis identifies epigenetic differences in Alzheimer’s disease and frontotemporal dementia in brain tissue and lymphoblastoid cell lines

Project description:We have performed methylation microarray analysis of two types of dementia, Alzheimer's disease (AD) and frontotemporal dementia (FTD), using two kind of samples, frozen brain tissue and lymphoblastoid cell lines.

2024-01-01 | E-MTAB-11975 | biostudies-arrayexpress

Molecular Signatures Underlying Selective Regional Vulnerability to Alzheimer's Disease

Project description:Alzheimer's disease (AD) is the most common form of dementia, characterized by progressive cognitive impairment and neurodegeneration as a result of abnormal neuronal loss. To elucidate the molecular systems associated with AD, we characterized the gene expression changes associated with multiple clinical and neuropathological traits in 1,053 postmortem brain samples across 19 brain regions from 125 persons dying with varying severities of dementia and variable AD-neuropathology severities. 125 human brains were accessed from the Mount Sinai/JJ Peters VA Medical Center Brain Bank (MSBB). This brain resource was assembled after applying stringent inclusion/exclusion criteria and represents the full spectrum of clinical and neuropathological disease severity in the absence of discernable non-AD neuropathology. RNA samples from 19 brain regions isolated from the 125 MSBB specimens were collected and profiled using Affymetrix Genechip microarrays. There were 50 to 60 subjects per brain region with varying degrees of AD pathological abnormalities.

2016-08-19 | E-GEOD-84422 | biostudies-arrayexpress

Epigenome-Wide Association Study of the Interaction between Alzheimer’s disease and Systemic Infection

Project description:Although most Alzheimer’s disease (AD) cases are sporadic, with no known aetiology, the onset and progression of the disease has been widely linked with inflammation both in the periphery and within the brain. Indeed, many AD sufferers ultimately die with a systemic infection, and infections during life can increase the risk of developing dementia and the rate of cognitive decline in AD patients. However, the mechanistic pathways linking inflammatory processes to AD onset and progression are not known. This study will use an epigenomic approach to elucidate the molecular mechanisms involved in the brain in AD following systemic inflammation. A better understanding of the neurobiological pathways altered in AD during systemic inflammation could ultimately identify new pharmacological targets, potentially improving the lives of millions of AD sufferers worldwide. This work identifies molecular mechanisms that are altered in AD brain during systemic inflammation, which can then be functionally characterised and targeted in in vitro modelling systems.

2025-04-11 | GSE284764 | GEO

The role of gliovascular crosstalk between vascular pathology and Alzheimer’s disease

Project description:Alzheimer's disease (AD) frequently occurs alongside cerebrovascular pathology (CVP), which together exacerbate cognitive decline and dementia. Gaining insights into the molecular interactions between these conditions is crucial for creating effective treatments that can tackle the complexities of AD. To determine impact of gliovascular interactions on the blood-brain-barrier (BBB) experimentally, we utilized a well-established zebrafish model.We treated double transgenic (Tg(fli1a:eGFP)/Tg(her4.1:dRFP)) zebrafish with vegf receptor inhibitor cocktails to evaluate the BBB integrity. By blocking VEGF signaling we showed that astroglial-endothelial interactions are essential for BBB integrity.

2026-07-02 | GSE269111 | GEO

Investigation of androgen receptor signaling in aged and Alzheimer's disease brains

Project description:Androgen signaling via the androgen receptor (AR), a ligand-dependent transcription factor within the steroid receptor superfamily, plays a vital role in the development and regulation of neuronal activity. Despite this, the mechanisms by which AR signaling is sustained or altered in human brain tissues remain unexplored. To deepen our understanding of AR function in the human brain, we conducted ChIP-seq (chromatin immunoprecipitation followed by sequencing) to identify AR and its associated transcription factors binding sites, and histone-acetylated regions in brain tissues from elderly individuals and patients with Alzheimer's disease (AD).

2026-09-09 | GSE295402 | GEO

Molecular Signatures Underlying Selective Regional Vulnerability to Alzheimer's Disease

2016-08-19 | GSE84422 | GEO